T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis

Leukemia, Lymphocytic, Acute Clinical Trial

Official title:

T-cell MRD Evaluation Using Flow Cytometric Analysis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01078337
• Other study ID #: SU-11022007-790
• Secondary ID: PEDSALL0001
• Status: Completed
• Phase: N/A
• First received: February 26, 2010
• Last updated: March 1, 2010
• Start date: November 2002
• Est. completion date: October 2007

Study information

• Verified date: February 2010
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

To determine if MRD (minimal residual disease) can be found in the blood (only) as opposed to bone marrow in children with ALL (acute lymphoblastic leukemia).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: October 2007
• Est. primary completion date: October 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 18 Years

Eligibility

Inclusion Criteria:

• Children with newly diagnosed T-cell ALL

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Leukemia, Lymphocytic, Acute
• Leukemia, Lymphoid
• Neoplasm, Residual
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Procedure:
• bone marrow aspiration

• peripheral blood sampling

Locations

Country	Name	City	State
United States	Stanford University School of Medicine	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States,